^
Association details:
Biomarker:EGFR expression
Cancer:Non Small Cell Lung Cancer
Drug Class:PD-L1 inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.

Published date:
05/13/2020
Excerpt:
...In multivariate Cox regression analysis, active BM, poor PS and EGFR..(+) were selected as significant factors associated with poor PFS….Anti-PD-(L)1 monotherapy is not recommend for pts with active BMs.
DOI:
10.1200/JCO.2020.38.15_suppl.e14511